Array
(
[id] => 1262
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1262.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => we recommend that for rivaroxaban, apixaban and edoxaban, the time from last drug intake to intervention should be 3 days, pending a creatinine clearance (Cockcroft–Gault formula) above 30 ml/min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 对于利伐沙班、阿哌沙班和依度沙班，建议从最后一次服药到手术的时间应为3 d，等待肌酐清除率> 30 ml·min-1。不建议桥接。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于利伐沙班、阿哌沙班和依度沙班，建议从最后一次服药到手术的时间应为3 d，等待肌酐清除率> 30 ml·min-1。不建议桥接。（证据级别：低；推荐强度：强推荐）
we recommend that for rivaroxaban, apixaban and edoxaban, the time from last drug intake to intervention should be 3 days, pending a creatinine clearance (Cockcroft–Gault formula) above 30 ml/min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1263
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1263.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => we recommend that for dabigatran, the time from last drug intake to intervention should be 3 days, if the creatinine clearance is above 50 ml /min , and 5 days if the creatinine clearance is between 30 and 50 ml /min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 对于达比加群，如果肌酐清除率> 50 ml·min-1，建议末次服药至手术的时间为3 d，如果肌酐清除率在30 ~ 50 ml min-1，建议为5 d。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于达比加群，如果肌酐清除率> 50 ml·min-1，建议末次服药至手术的时间为3 d，如果肌酐清除率在30 ~ 50 ml min-1，建议为5 d。（证据级别：低；推荐强度：强推荐）
we recommend that for dabigatran, the time from last drug intake to intervention should be 3 days, if the creatinine clearance is above 50 ml /min , and 5 days if the creatinine clearance is between 30 and 50 ml /min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1264
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1264.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that in severe bleeding patients treated with dabigatran, a specific antidote (idarucizumab) could be considered.（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于接受达比加群治疗的严重出血患者，可以考虑使用特效药物——依达赛珠单抗(idarucizumab)。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于接受达比加群治疗的严重出血患者，可以考虑使用特效药物——依达赛珠单抗(idarucizumab)。（证据级别：低；推荐强度：弱推荐）
We suggest that in severe bleeding patients treated with dabigatran, a specific antidote (idarucizumab) could be considered.（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1265
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1265.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that for low-bleeding-risk procedures, when haemostasis is achieved, DOACs should be restarted about 6 h after the procedure without LMWH administration.(rivaroxaban, apixaban and edoxaban).（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于出血风险低的手术，在达到止血后，在不给予LMWH的情况下，DOACs应在术后 6h重新启动。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于出血风险低的手术，在达到止血后，在不给予LMWH的情况下，DOACs应在术后 6h重新启动。（证据级别：低；推荐强度：弱推荐）
We suggest that for low-bleeding-risk procedures, when haemostasis is achieved, DOACs should be restarted about 6 h after the procedure without LMWH administration.(rivaroxaban, apixaban and edoxaban).（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1266
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1266.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Point-of-care tests of platelet function and bleeding time are not useful for predicting bleeding risk in uraemic patients undergoing invasive procedures. （ Evidence level: low；Recommendation grade: weak）
[laiyuan] => 床旁检测血小板功能和出血时间对于预测侵入性手术的贫血患者的出血风险并无用处。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
床旁检测血小板功能和出血时间对于预测侵入性手术的贫血患者的出血风险并无用处。（证据级别：低；推荐强度：弱推荐）
Point-of-care tests of platelet function and bleeding time are not useful for predicting bleeding risk in uraemic patients undergoing invasive procedures. （ Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1267
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1267.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Desmopressin therapy is suggested in high-risk uraemic patients for reducing bleeding during invasive procedures and for managing acute bleeding. （ Evidence level: low；Recommendation grade: weak）
[laiyuan] => 建议对高风险尿毒症患者进行去氨加压素治疗，以减少侵入性手术期间的出血量并控制急性出血。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
建议对高风险尿毒症患者进行去氨加压素治疗，以减少侵入性手术期间的出血量并控制急性出血。（证据级别：低；推荐强度：弱推荐）
Desmopressin therapy is suggested in high-risk uraemic patients for reducing bleeding during invasive procedures and for managing acute bleeding. （ Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1268
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1268.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Conjugated oestrogen therapy could be considered in uraemic platelet dysfunction. （ Evidence level: low；Recommendation grade: weak）
[laiyuan] => 尿毒症血小板功能障碍患者可考虑结合雌激素疗法。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
尿毒症血小板功能障碍患者可考虑结合雌激素疗法。（证据级别：低；推荐强度：弱推荐）
Conjugated oestrogen therapy could be considered in uraemic platelet dysfunction. （ Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1220
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1220.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:26
[updatetime] => 2024-01-11 15:24:26
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative anaemia in adults and children appears to be a strong predictor for peri-operative blood transfusion across various types of conditions, and procedures and is associated with adverse events.（Recommendation grade:Strong）
[laiyuan] => 成人和儿童的术前贫血是围手术期输血的强预测因素，并与不良事件相关。（推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957866
[_updatetime] => 1704957866
[_nrjc] =>
[_nrsh] =>
)
推荐意见
成人和儿童的术前贫血是围手术期输血的强预测因素，并与不良事件相关。（推荐强度：强推荐）
Pre-operative anaemia in adults and children appears to be a strong predictor for peri-operative blood transfusion across various types of conditions, and procedures and is associated with adverse events.（Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1221
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1221.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:26
[updatetime] => 2024-01-11 15:24:26
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend that patients at risk of bleeding are assessed for anaemia well before surgery in order to permit time for anaemia correction if needed. （Evidence level: moderate；Recommendation grade: strong）
[laiyuan] => 我们推荐有出血风险的患者在术前应充分评估贫血情况，以便在需要时给予纠正贫血的时间。（证据级别：中；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957866
[_updatetime] => 1704957866
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们推荐有出血风险的患者在术前应充分评估贫血情况，以便在需要时给予纠正贫血的时间。（证据级别：中；推荐强度：强推荐）
We recommend that patients at risk of bleeding are assessed for anaemia well before surgery in order to permit time for anaemia correction if needed. （Evidence level: moderate；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1222
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => https://www.anes-guide.com/show/1222.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:26
[updatetime] => 2024-01-11 15:24:26
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest a time interval of 1 to 2 weeks in cases of parenteral stimulation of erythropoiesis and uncomplicated cause of anaemia, whereas 3 to 8 weeks may be required in cases of oral correction of iron deficiency anaemia (IDA) and complex causes of anaemia. （Evidence level: moderate；Recommendation grade: weak）
[laiyuan] => 对于非消化道刺激红细胞生成和无复杂原因的贫血，我们建议间隔1 -2w，而对于口服纠正缺铁性贫血(IDA)和复杂原因的贫血，可能需要3-8w。（证据级别：中；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957866
[_updatetime] => 1704957866
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于非消化道刺激红细胞生成和无复杂原因的贫血，我们建议间隔1 -2w，而对于口服纠正缺铁性贫血(IDA)和复杂原因的贫血，可能需要3-8w。（证据级别：中；推荐强度：弱推荐）
We suggest a time interval of 1 to 2 weeks in cases of parenteral stimulation of erythropoiesis and uncomplicated cause of anaemia, whereas 3 to 8 weeks may be required in cases of oral correction of iron deficiency anaemia (IDA) and complex causes of anaemia. （Evidence level: moderate；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
